Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mechanism study of acetylshikonin on attenuation with cardiomyopathy of diabetic mice via mTOR signaling pathway

ABSTRACT: Diabetic cardiomyopathy (DCM) is a complication of diabetes, which may be associated with a great risk of mortality. Comprehensively understanding the effects and mechanisms of acetylshikonin (AS) on the attenuation of DCM will be helpful for the innovative drug investigation and clinical application. This study aimed to explore the possible links and signaling pathways between AS and DCM. A cohort of diabetic mice was established based on disease model (Model, AS, Control groups), and their serum samples were collected for non-targeted metabolomics. The high resolution mass spectrometry data among the three groups were analyzed by combining multivariate and univariate statistical methods. The differential metabolites and altered metabolic pathways were screened out and identified by examining the Kyoto Encyclopedia of Genes and Genomes database, respectively.

ORGANISM(S): Mus Sp.

SUBMITTER: Wendong Huang

PROVIDER: PXD037646 | iProX | Sun Oct 23 00:00:00 BST 2022

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

RNA Sequencing of Cardiac in STZ-induced Rat model Uncovers Potential Target of Diabetic cardiomyopathy

Project description:Diabetic cardiomyopathy (DCM) is one of the major causes of heart failure in diabetic patients, but its pathogenesis remains unclear. Long non-coding RNAs (lncRNAs) are involved in the development of various cardiovascular diseases, but is little known in DCM. We build diabetic cardiomyopathy (DCM) rat model and investigated the genome-wide expression profiling of cardiac lncRNAs and mRNAs in rat model with and without DCM by RNA sequencing, to uncovers potential path mechanisms target of DCM.

2022-03-13 | GSE197999 | GEO

Proteomic Analysis insights into Potential Mechanism of SGLT2 Inhibitors cardiovascular benefit in Diabetic cardiomyopathy

Project description:Diabetic cardiomyopathy (DCM) is one of the major causes of heart failure in diabetic patients, but its pathogenesis remains unclear. Sodium glucose cotransporter 2 inhibitors (SGLT2i) can effectively reduce the risk of cardiovascular death and heart failure in DCM patients, but the underlying mechanism has not been elucidated. We established a DCM rat model followed by treatment with empagliflozin (EMPA) for 12 weeks. The proteomics of the myocardium in the rat model was performed to identify the potential targets and signaling pathways associated with the cardiovascular benefit of SGLT2i.

2023-03-10 | PXD036090 | Pride

Identification of Hub Genes and Potential ceRNA Networks of Diabetic Cardiomyopathy [miRNA-seq]

Project description:To explore the unique pathogenesis of DCM and analyzed the differences in gene expression, associated pathways and immune cell infiltration among different organs that are targeted by high glucose by bioinformatics-based strategy. In order to find the specific factors that trigger DCM, we contrasted the gene profile of DCM to that of other diabetic diseases including diabetic peripheral neuropathy (DPN) and nephropathy (DN). we performed RNA-seq and miRNA sequencing on heart tissue from db/db mice to explore the transcriptome alterations in DCM pathogenesis including lncRNA, miRNA and mRNA.

2023-05-10 | GSE211107 | GEO

Identification of Hub Genes and Potential ceRNA Networks of Diabetic Cardiomyopathy [RNA-seq]

2023-05-10 | GSE211106 | GEO

Inhibition of HMOX1 alleviates diabetic cardiomyopathy by targeting ferroptosis

Project description:Diabetic cardiomyopathy (DCM) is an important complication of chronic diabetes mellitus (DM). However, its pathogenesis and pathologic process have not been fully elucidated. This study was aimed to investigate the role of ferroptosis in the pathogenesis of DCM and clarify the effect of HMOX1 on DCM by targeting ferroptosis. DCM mouse model was constructed by high fat diet (HFD) feeding and streptozotocin (STZ). injection.

2023-08-28 | GSE241166 | GEO

Disruption of BCAAs degradation is the primary mechanism of diabetic cardiomyopathy revealed by integrated transcriptome and metabolome analysis

Project description:Diabetic cardiomyopathy (DCM) is a unique form of cardiomyopathy observed in diabetic patients, and in this study we aimed to gain a comprehensive understanding of the underlying mechanisms of DCM by integrating transcriptomics and metabolomics

2025-01-22 | GSE267352 | GEO

Streptozotocin-induced Type 1 and 2 Diabetes Mellitus Mouse Models Show Different Functional, Cellular and Molecular Patterns of Diabetic Cardiomyopathy

Project description:The main cause of morbidity and mortality in diabetes mellitus (DM) are cardiovascular complications. Diabetic cardiomyopathy (DCM) remains incompletely understood. Animal models have been crucial in exploring DCM pathophysiology while identifying potential therapeutic targets. Streptozotocin (STZ) has been widely used to produce experimental models of both type 1 and type 2 DM (T1DM and T2DM). Here we compared these two models for their effects on cardiac structure, function, and transcriptome. Different doses of STZ and different diet chows were used to generate T1DM and T2DM in C57BL/6J mice. Normal euglycemic and non-obese sex and age-matched mice served as controls (CTRL). Immunohistochemistry, RT-PCR, and RNA-Seq were employed to compare hearts from the three animal groups. STZ-induced T1DM and T2DM differently affect left ventricular function and myocardial performance. T1DM displays an exaggerated apoptotic cardiomyocyte (CM) death and reactive hypertrophy and fibrosis along with increased cardiac oxidative stress, CM DNA damage and senescence when compared to T2DM mice. T1DM and T2DM differently affect whole cardiac transcriptome. In conclusion, STZ-induced T1DM and T2DM mouse models show significant differences in cardiac remodeling, function and whole transcriptome. These differences could be of key relevance when choosing an animal model to study specific features of DCM.

2023-02-20 | E-MTAB-12558 | biostudies-arrayexpress

MS-based quantitative proteomic analysis of MAM from WT and obese mice.

Project description:Diabetic cardiomyopathy (DCM) strongly leads to heart failure, notably with preserved ejection fraction (HFpEF). The involvement of mitochondria-associated reticular membranes (MAM) in T2D-related metabolic disorders starts to be demonstrated. In order to characterize the cardiac phenotype of an obesogenic type II diabetic mouse model (leptin-deficient ob/ob), we compared the proteome of its MAMs with those from WT mice.

2025-06-16 | PXD054672 | Pride

PROTEOMIC ANALYSIS OF EARLY DIABETIC RETINOPATHY REVEALS MEDIATORS OF NEURODEGENERATIVE BRAIN DISEASES

Project description:The aim of the present study was to identify early changes in diabetic retinas using an unbiased proteomics approach. Proteomic profiles of control retinas were compared to diabetic retinas obtained from patients known to have no classic vascular lesions that clinically define diabetic retinas. The diabetic retinas were further split into two groups according to the presence or absence of glial activation as marker of progressive changes that may be associated with the early neurodegenerative process. By examining differentially expressed proteins at this preclinical stage, our aim was to acquire a clearer understanding of the complex cellular processes that initiate diabetic retinas.

2022-03-02 | PXD008989 | Pride

MeRIP sequencing

Project description:In this study, we aimed to systematically profile global RNA N6-methyladenosine (m6A) modification patterns in a mouse model of diabetic cardiomyopathy (DCM). Patterns of m6A in DCM and normal hearts were analyzed via m6A-specific methylated RNA immunoprecipitation followed by high-throughput sequencing (MeRIP-seq) and RNA sequencing (RNA-seq). A total of 973 m6A peaks were detected in DCM samples and 296 differentially methylated sites were selected for further study, including 106 hypermethylated and 190 hypomethylated m6A sites (fold change (FC) > 2, p < 0.05). Gene ontology and KEGG Pathway analyses indicated that unique m6A-modified transcripts in DCM were closely linked to cardiac fibrosis, myocardial hypertrophy, and myocardial energy metabolism. Overall, m6A modification patterns were altered in DCM, and modification of epitranscriptomic processes, such as m6A, is a potentially interesting therapeutic approach.

2021-05-25 | GSE173384 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data